Pharma Reviews: Pharma's stumble after six-year run may offer value buys

"Because of this tightening of (US) FDA regulations, there are observations or import bans on plants of Indian pharma companies. This is responsible ...
Read more: Pharma's stumble after six-year run may offer value buys